Increasing R&D Activities In The Global Gastrointestinal Drugs Market

The gastrointestinal diseases drugs market covers medicines used for the treatment of ulcerative colitis, diverticular disease, perianal infections, anal fissures, hemorrhoids, constipation, and irritable bowel syndrome. The key gastrointestinal...

The gastrointestinal diseases drugs market covers medicines used for the treatment of ulcerative colitis, diverticular disease, perianal infections, anal fissures, hemorrhoids, constipation, and irritable bowel syndrome. The key gastrointestinal diseases drug categories include Anti-peptic agents (antacids, antagonists, Proton Pump Inhibitors, Sucralfate, and Misoprostol), antiemetics, adsorbents, anticholinergics, opiates, intestinal flora modifiers, emollient/surfactants, hyperosmotic, saline, and simulant/irritant. The market numbers within this briefing are restricted to pharmaceutical (drug) treatments and do not cover biologic treatments for these conditions which are included in a separate briefing.

Order report at:

https://www.thebusinessresearchcompany.com/report/gastrointestinal-drugs-global-market-report-2018

The global gastrointestinal drugs market has been growing in the past years with a CAGR of almost 3%. The year 2017 recorded high growth in this market with a net market value more than 9% higher than that of 2013, as per TBRC’s in-house consultants.

TBRC’s latest report show the historic and future trends in the market for each year with sourced reasons to support the growth claims.

The report also shows the global gastrointestinal drugs market to grow at a higher CAGR by 2021 as compared to 2017, along with geographies best suited for investments with highest return rate.

Download sample report at:

https://www.thebusinessresearchcompany.com/sample.aspx?id=273&type=smp

Growing R&D activities for the development of new drugs in the treatment of gastrointestinal diseases is an emerging trend in the market. Some of the major gastrointestinal pipeline products include Perjeta (Roche), Keytruda (Merck), TAS-118 (Taiho Pharmaceutical), NeuVax (Galena Biopharma), Ipatasertib (Genentech), Durvalumab (AstraZeneca) and Napabucasin (Boston Biomedical). Technological advances in the treatment of gastrointestinal diseases are expected to boost the market during the forecast period.

Companies included in the report are Takeda Pharmaceuticals, Allergan Plc., and Novo Nordisk A/S.

About The Business Research Company:

The Business Research Company is a Business Intelligence Company which excels in company, market and consumer research. It has offices in the UK, the US and India and a network of trained researchers in 15 countries globally.

Contact Information

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 8897263534

Americas: +1 315 623 0293

Email: [email protected]

Follow us on LinkedIn: https://in.linkedin.com/company/the-business-research-company

 

Categories
Business
No Comment

Leave a Reply

*

*